Hester Biosciences Limited (HESTERBIO) AI Stock Analysis

• Market Cap: ₹16.48B
• Dividend Yield: 0.36%
• Average Volume (3M): 1.29K
• Price to Earnings (P/E): 43.8
• Beta (1Y): 0.45
• Revenue Growth: 4.68%
• EPS Growth: 94.22%
• Country: IN
• Employees: 642
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 19.33
• Shares Outstanding: 8,506,865
• 10 Day Avg. Volume: 3,165
• 30 Day Avg. Volume: 1,292
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,380.00
• Price Target Upside: 21.89% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: ₹2,380.00 ▲(21.89% Upside)

Hester Biosciences Limited receives a score of 68, driven primarily by strong financial performance, including robust revenue growth and cash flow generation. Positive technical indicators support the stock's momentum, but the overbought RSI suggests caution. The high P/E ratio and low dividend yield indicate potential overvaluation, which negatively impacts the overall score.

Hester Biosciences Limited Business Overview & Revenue Model

Company Description

Hester Biosciences Limited (HESTERBIO) is a leading animal healthcare company headquartered in India, specializing in the production and distribution of vaccines and health products for poultry and livestock. The company operates in the biotechnology sector, focusing on animal health and veterinary biologicals. Hester Biosciences is known for its comprehensive range of products, including vaccines for poultry, large animals, and companion animals, as well as health products aimed at improving animal productivity and welfare.

How the Company Makes Money

Hester Biosciences Limited generates revenue primarily through the sale of its veterinary vaccines and health products. The company's revenue streams include the sale of poultry vaccines, large animal vaccines, and companion animal vaccines, each catering to different segments of the animal healthcare market. Additionally, Hester Biosciences offers health products that enhance animal productivity and well-being. The company may also engage in strategic partnerships and collaborations with other entities to expand its market reach and product offerings. Key factors contributing to its earnings include the demand for animal healthcare products, advancements in vaccine technology, and the expansion of its distribution network both domestically and internationally.

Hester Biosciences Limited Financial Statement Overview

Summary

Hester Biosciences Limited demonstrates strong financial health across its income statement, balance sheet, and cash flow metrics. The company shows significant revenue and profit growth with improving margins, a balanced financial structure, and robust cash flow generation. However, the increase in debt should be monitored to prevent potential financial strain.

Income Statement

The company's revenue growth is robust, with consistent upward trends over the years, including a significant spike in gross profit margins. EBIT and EBITDA margins have shown improvement, indicating operational efficiency. The net profit margin has remained stable, showing consistent profitability.

Balance Sheet

The company maintains a solid equity base with a moderate debt-to-equity ratio, indicating balanced leverage. The return on equity shows steady profitability relative to shareholder equity. The equity ratio indicates a sound financial structure, but the increase in total debt requires close monitoring.

Cash Flow

Positive free cash flow growth highlights effective cash management despite significant capital expenditures. The operating cash flow to net income ratio suggests healthy cash generation. The free cash flow to net income ratio shows improvement, reflecting better cash conversion efficiency.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.11B	3.05B	2.66B	2.35B	2.14B
Gross Profit	2.27B	972.64M	1.89B	1.66B	1.58B
EBITDA	649.76M	582.46M	619.20M	731.93M	700.21M
Net Income	274.88M	188.89M	266.27M	393.20M	344.30M
Balance Sheet
Total Assets	6.53B	6.62B	5.46B	5.62B	4.11B
Cash, Cash Equivalents and Short-Term Investments	72.19M	153.04M	226.08M	256.73M	211.00M
Total Debt	2.13B	2.44B	1.64B	2.28B	1.10B
Total Liabilities	3.27B	3.59B	2.53B	2.95B	1.75B
Stockholders Equity	3.14B	2.92B	2.92B	2.60B	2.28B
Cash Flow
Free Cash Flow	439.20M	237.37M	-541.66M	-869.02M	173.11M
Operating Cash Flow	645.11M	481.34M	235.96M	88.08M	580.53M
Investing Cash Flow	-190.03M	-226.54M	-769.99M	-1.17B	-383.72M
Financing Cash Flow	-517.17M	-260.45M	417.58M	1.12B	-182.19M

Hester Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1952.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Neutral. The current price of 1952.6 is above the 20-day moving average (MA) of 1922.94, above the 50-day MA of 1856.85, and below the 200-day MA of 1965.95, indicating a neutral trend. The MACD of 49.15 indicates Negative momentum. The RSI at 53.19 is Neutral, neither overbought nor oversold. The STOCH value of 33.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:HESTERBIO.

Hester Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HESTERBIO	68 Neutral	₹16.48B	43.83		0.36%	4.68%	94.22%
MOREPENLAB	65 Neutral	₹25.58B	27.74		―	2.12%	-25.99%
Sector *	64 Neutral	CHF26.61B	17.29	9.71%	2.35%	21.08%	2.84%
GUFICBIO	59 Neutral	₹35.51B	50.95		0.03%	2.37%	-30.78%
UNICHEMLAB	58 Neutral	₹34.11B	26.07		―	22.04%	―
SEQUENT	52 Neutral	₹43.62B	198.76		―	13.26%	―
INDOCO	47 Neutral	₹26.90B	96.22		0.53%	-8.28%	-247.34%